Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.

Siwakoti, P; Rennie, C; Huang, Y; Li, JJ; Tuch, BE; McClements, L; Xu, X

Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.

Siwakoti, P Rennie, C Huang, Y Li, JJ Tuch, BE McClements, L

Xu, X

Permalink

Publisher:: SPRINGER
Publication Type:: Journal Article
Citation:: Stem Cell Rev Rep, 2022
Issue Date:: 2022-11-25

Closed Access

	Filename	Description	Size
	2023-Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.pdf	Published version	2.54 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Siwakoti, P
dc.contributor.author	Rennie, C
dc.contributor.author	Huang, Y
dc.contributor.author	Li, JJ
dc.contributor.author	Tuch, BE
dc.contributor.author	McClements, L https://orcid.org/0000-0002-4911-1014
dc.contributor.author	Xu, X https://orcid.org/0000-0002-2598-3766
dc.date.accessioned	2023-01-18T04:06:02Z
dc.date.available	2022-11-13
dc.date.available	2023-01-18T04:06:02Z
dc.date.issued	2022-11-25
dc.identifier.citation	Stem Cell Rev Rep, 2022
dc.identifier.issn	2629-3269
dc.identifier.issn	2629-3277
dc.identifier.uri	http://hdl.handle.net/10453/165102
dc.description.abstract	Type 1 diabetes (T1D) is a chronic, lifelong metabolic disease. It is characterised by the autoimmune-mediated loss of insulin-producing pancreatic β cells in the islets of Langerhans (β-islets), resulting in disrupted glucose homeostasis. Administration of exogenous insulin is the most common management method for T1D, but this requires lifelong reliance on insulin injections and invasive blood glucose monitoring. Replacement therapies with beta cells are being developed as an advanced curative treatment for T1D. Unfortunately, this approach is limited by the lack of donated pancreatic tissue, the difficulties in beta cell isolation and viability maintenance, the longevity of the transplanted cells in vivo, and consequently high costs. Emerging approaches to address these limitations are under intensive investigations, including the production of insulin-producing beta cells from various stem cells, and the development of bioengineered devices including nanotechnologies for improving islet transplantation efficacy without the need for recipients taking toxic anti-rejection drugs. These emerging approaches present promising prospects, while the challenges with the new techniques need to be tackled for ultimately clinical treatment of T1D. This review discussed the benefits and limitations of the cell-based therapies for beta cell replacement as potential curative treatment for T1D, and the applications of bioengineered devices including nanotechnology to overcome the challenges associated with beta cell transplantation.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	SPRINGER
dc.relation.ispartof	Stem Cell Rev Rep
dc.relation.isbasedon	10.1007/s12015-022-10482-1
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.
dc.type	Journal Article
utslib.location.activity	United States
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	closed_access	*
dc.date.updated	2023-01-18T04:06:00Z
pubs.publication-status	Published online

Abstract:

Type 1 diabetes (T1D) is a chronic, lifelong metabolic disease. It is characterised by the autoimmune-mediated loss of insulin-producing pancreatic β cells in the islets of Langerhans (β-islets), resulting in disrupted glucose homeostasis. Administration of exogenous insulin is the most common management method for T1D, but this requires lifelong reliance on insulin injections and invasive blood glucose monitoring. Replacement therapies with beta cells are being developed as an advanced curative treatment for T1D. Unfortunately, this approach is limited by the lack of donated pancreatic tissue, the difficulties in beta cell isolation and viability maintenance, the longevity of the transplanted cells in vivo, and consequently high costs. Emerging approaches to address these limitations are under intensive investigations, including the production of insulin-producing beta cells from various stem cells, and the development of bioengineered devices including nanotechnologies for improving islet transplantation efficacy without the need for recipients taking toxic anti-rejection drugs. These emerging approaches present promising prospects, while the challenges with the new techniques need to be tackled for ultimately clinical treatment of T1D. This review discussed the benefits and limitations of the cell-based therapies for beta cell replacement as potential curative treatment for T1D, and the applications of bioengineered devices including nanotechnology to overcome the challenges associated with beta cell transplantation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165102